Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Long-Term Investments (2019)

Historic Long-Term Investments for China SXT Pharmaceuticals (SXTC) over the last 4 years, with Q3 2022 value amounting to $1.6 million.

  • China SXT Pharmaceuticals' Long-Term Investments changed 0.0% to $1.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was $1.6 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $1.6 million for FY2022, which is 0.0% changed from last year.
  • According to the latest figures from Q3 2022, China SXT Pharmaceuticals' Long-Term Investments is $1.6 million, which was down 0.0% from $1.6 million recorded in Q1 2022.
  • China SXT Pharmaceuticals' Long-Term Investments' 5-year high stood at $1.6 million during Q3 2020, with a 5-year trough of -$3.6 million in Q3 2019.
  • For the 4-year period, China SXT Pharmaceuticals' Long-Term Investments averaged around $840764.9, with its median value being $1.6 million (2021).
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Long-Term Investments surged by 14449.18% in 2020, and later plummeted by 167.91% in 2021.
  • Over the past 4 years, China SXT Pharmaceuticals' Long-Term Investments (Quarter) stood at -$3.6 million in 2019, then skyrocketed by 144.49% to $1.6 million in 2020, then dropped by 1.68% to $1.6 million in 2021, then changed by 0.0% to $1.6 million in 2022.
  • Its Long-Term Investments stands at $1.6 million for Q3 2022, versus $1.6 million for Q1 2022 and $1.6 million for Q3 2021.